HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.

Abstract
The need for daily parenteral administration represents one of the most serious limitations in the clinical use of pentavalent antimonials against leishmaniasis. In this work, we investigated the ability of beta-cyclodextrin to enhance the oral absorption of antimony and to promote the oral efficacy of meglumine antimoniate against experimental cutaneous leishmaniasis. The occurrence of interactions between beta-cyclodextrin and meglumine antimoniate was demonstrated through the changes induced in the spin lattice relaxation times of protons in both compounds. When free and complexed meglumine antimoniate were given orally to Swiss mice, plasma antimony levels were found to be about three times higher for the meglumine antimoniate-beta-cyclodextrin complex than for the free drug. Antileishmanial efficacy was evaluated in BALB/c mice experimentally infected with Leishmania amazonensis. Animals treated daily with the complex (32 mg of Sb/kg of body weight) by the oral route developed significantly smaller lesions than those treated with meglumine antimoniate (120 mg of Sb/kg) and control animals (treated with saline). The effectiveness of the complex given orally was equivalent to that of meglumine antimoniate given intraperitoneally at a twofold-higher antimony dose. The antileishmanial efficacy of the complex was confirmed by the significantly lower parasite load in the lesions of treated animals than in saline-treated controls. This work reports for the first time the effectiveness of an oral formulation for pentavalent antimonials.
AuthorsCynthia Demicheli, Rosemary Ochoa, José B B da Silva, Camila A B Falcão, Bartira Rossi-Bergmann, Alan L de Melo, Ruben D Sinisterra, Frédéric Frézard
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 48 Issue 1 Pg. 100-3 (Jan 2004) ISSN: 0066-4804 [Print] United States
PMID14693525 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiprotozoal Agents
  • Cyclodextrins
  • Organometallic Compounds
  • beta-Cyclodextrins
  • Meglumine
  • Meglumine Antimoniate
  • betadex
Topics
  • Administration, Oral
  • Animals
  • Antiprotozoal Agents (administration & dosage, therapeutic use)
  • Chemical Phenomena
  • Chemistry, Physical
  • Cyclodextrins (administration & dosage, chemistry, therapeutic use)
  • Injections, Intraperitoneal
  • Intestinal Absorption
  • Leishmania mexicana
  • Leishmaniasis, Cutaneous (drug therapy, parasitology)
  • Male
  • Meglumine (administration & dosage, chemical synthesis, therapeutic use)
  • Meglumine Antimoniate
  • Mice
  • Mice, Inbred BALB C
  • Organometallic Compounds (administration & dosage, chemical synthesis, therapeutic use)
  • beta-Cyclodextrins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: